T1	intervention 30 39	docetaxel
T2	control 54 64	paclitaxel
T3	eligibility 204 315	patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen
T4	total-participants 331 334	449
T5	intervention-participants 402 405	225
T6	control-participants 436 439	224
T7	outcome 583 606	median overall survival
T8	iv-cont-median 612 616	15.4
T9	cv-cont-median 619 630	12.7 months
T13	iv-cont-median 729 739	5.7 months
T14	cv-cont-median 742 752	3.6 months
T17	outcome 866 887	overall response rate
T18	iv-bin-percent 894 897	32%
T19	cv-bin-percent 900 903	25%
T10	outcome 1269 1271	OS
T11	outcome 1276 1279	TTP
T15	outcome 1281 1284	ORR
T16	outcome 1311 1352	Hematologic and nonhematologic toxicities
T12	outcome 696 722	median time to progression
T20	outcome 1030 1071	hematologic and nonhematologic toxicities
T21	outcome 889 892	ORR
